CoChat

Exenatide (Byetta) as a Novel Treatment Option for Type 2 Diabetes Mellitus

Open access
Bond, Aaron · 2006 · Baylor University Medical Center Proceedings
Cited by 87

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Exenatide is the first drug in the incretin mimetic class and is indicated for treatment of type 2 diabetes mellitus. Although structurally similar to the native glucagon-like peptide, this synthetic form has a much longer duration of action. Randomized trials have shown exenatide to be efficacious in improving glycemic control when combined with either metformin or a sulfonylurea. The dose is initially 5 mcg subcutaneously twice daily and may be titrated to 10 mcg subcutaneously twice daily to achieve better diabetes management. Nausea, vomiting, and diarrhea were the most common adverse events reported with exenatide therapy. Exenatide is not associated with hypoglycemia, which may provide advantages over adding insulin to a sulfonylurea or metformin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/08998280.2006.11928181

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 4

  1. Amylin Pharmaceuticals, Inc., 2005, Byetta [package insert]
  2. Meneilly GS, 2003, Diabetes Care, 26, 2835, 10.2337/diacare.26.10.2835 · DOI · Paper page
  3. Drucker DJ, 1998, Diabetes, 47, 159, 10.2337/diab.47.2.159 · DOI · Paper page
  4. Parkes DG, 2001, Metabolism, 50, 583, 10.1053/meta.2001.22519 · DOI · Paper page

Cited by

See all 87

Metadata

Authors
Bond, A.
Venue
Baylor University Medical Center Proceedings
Published
2006-07
Volume
19
Issue
3
Pages
281-284
ISSN
  • 0899-8280 (ISSN-L)
  • 1525-3252
OpenAlex
W1650430460
Cited by
87
References
4
FWCI
0.81
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exenatide (Byetta) as a Novel Treatment Option for Type 2 Diabetes Mellitus. https://app.cochat.ai/papers/10.1080/08998280.2006.11928181
The paper
Bond, A. (2006). Exenatide (Byetta) as a Novel Treatment Option for Type 2 Diabetes Mellitus. Baylor University Medical Center Proceedings. https://doi.org/10.1080/08998280.2006.11928181

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.